| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-143SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-355SS | |||
| Azide and BSA Free | NBP2-80931 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide Free | NB300-110SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Unpurified | NB600-1252-0.1ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-232SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2288SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27103SS | |||
| Azide and BSA Free | NBP2-80749 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-40763SS | |||
![Immunohistochemistry: GFAP Antibody [NB300-141] - Analysis of a rat cerebellum section stained with rabbit polyclonal antibody to GFAP, NB300-141, dilution 1:5000 in green and mouse monoclonal antibody to MeCP2, dilution 1:500, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 1 hour, cut to 45 uM, and free-floating sections were stained with above antibodies. The GFAP antibody stains the network of astrocytic cells and the processes of Bergmann glia in the molecular layer. The MeCP2 antibody specifically labels nuclei of certain neurons.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0011.jpg "Immunohistochemistry: GFAP Antibody [NB300-141] - Analysis of a rat cerebellum section stained with rabbit polyclonal antibody to GFAP, NB300-141, dilution 1:5000 in green and mouse monoclonal antibody to MeCP2, dilution 1:500, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 1 hour, cut to 45 uM, and free-floating sections were stained with above antibodies. The GFAP antibody stains the network of astrocytic cells and the processes of Bergmann glia in the molecular layer. The MeCP2 antibody specifically labels nuclei of certain neurons.")
![Immunocytochemistry/Immunofluorescence: GFAP Antibody [NB300-141] - Rat neurons stained with Neurofilament Heavy antibody NB300-217 (red) and GFAP antibody NB300-141 (green).](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0002.jpg)
![Simple Western: GFAP Antibody [NB300-141] - Simple Western lane view shows a specific band for GFAP in 0.05 mg/mL of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GFAP-Antibody-Simple-Western-NB300-141-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: GFAP Antibody [NB300-141] - The inhibition of Kv1.3 channels induces neuroprotection against the toxic effects of glioma. Immunofluorescence analyses of Kv1.3 expression (red) on GFAP-positive cells (green) in coronal brain slices of GL261-bearing mice in peritumoral region; in the magnification (right) arrows indicate co-expression of Kv1.3 and GFAP in the same cell. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-25940-5) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0014.jpg)
![Immunohistochemistry-Paraffin: GFAP Antibody [NB300-141] - Mouse brain section, 20x magnification. Antibody at 1:1000. Detection with Polymer-HRP. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunohistochemistry-Paraffin-NB300-141-img0013.jpg)
![Western Blot: GFAP Antibody [NB300-141] - Analysis of Rat brain lysate. Antibody at 1:5000. Specific band running with an apparent SDS-PAGE molecular weight of ~50 kDa corresponds to rodent GFAP was observed.](http://images.novusbio.com/fullsize/GFAP-Antibody-Western-Blot-NB300-141-img0006.jpg)
![Western Blot: GFAP Antibody [NB300-141] - Analysis of GFAP expression in whole rat cerebellum homogenate.](http://images.novusbio.com/fullsize/GFAP-Antibody-Western-Blot-NB300-141-img0009.jpg)
![Western Blot: GFAP Antibody [NB300-141] - Analysis of different tissue lysates using rabbit polyclonal antibody to GFAP, NB300-141, dilution 1:5000 in green: [1] protein standard (red), [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord. Strong band at about 50 kDa corresponds to the major isotype of the GFAP protein. Smaller isotypes and proteolytic fragments of GFAP are also detected on the blot.](http://images.novusbio.com/fullsize/GFAP-Antibody-Western-Blot-NB300-141-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: GFAP Antibody [NB300-141] - Analysis of mixed neuron-glial cultures using GFAP antibody NB300-141 (red) and Vimentin antibody NB300-223 (green). The fibroblastic cells contain only Vimentin and so are green. The astrocytes contain either Vimentin and GFAP (appearing golden) or predominantly GFAP (appearing red). Blue is nuclear DNA stain.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: GFAP Antibody [NB300-141] - Cultured Rat hippocampal neurons. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0008.jpg)
![Immunohistochemistry: GFAP Antibody [NB300-141] - Xenografted mouse brain section: astocyte and human nuclei. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-141-img0003.jpg)
![Immunohistochemistry-Frozen: GFAP Antibody [NB300-141] - Imaging of mouse brain (cortex), 20x magnification. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/GFAP-Antibody-Immunohistochemistry-Frozen-NB300-141-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: GFAP Antibody [NB300-141] - EGFP+ neurons are positive for RABV antigen.Brains were collected from Cre reporter mice fifteen days post-infection, cryosectioned, & EGFP+ regions compared to cell-specific labeling, A) NeuN (blue, neuronal nuclei antibody, 20× fluorescence imaging), B) GFAP (blue, astrocyte antibody, 40× confocal imaging), or C) RABV P antigen (purple) & DAPI nuclear stain (blue, 63× confocal imaging). White arrows in (C) indicate regions positive for RABV P. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1002971), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-141_rabbit-polyclonal-gfap-antibody-310202415293349.jpg)
![Western Blot: GFAP Antibody [NB300-141] - Effects of the repeated administration of NVP CXCR2 20 (NVP; 10 μg/5 μl; i.t.; 16 h & 1 h before CCI & then once a day for 7 days) on the protein levels of CXCR2, IBA1, GFAP, CXCL1, CXCL2, & CXCL3 proteins (A–I) in the spinal cord (A–F) & DRG (G–I) on the 7th day after CCI in rats. The data are presented as the mean fold changes relative to the control ± SEM (5–6 samples per group). Intergroup differences were analyzed using ANOVA with Bonferroni's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001 indicate differences vs. naive rats. #p < 0.05, indicate differences between V-treated & NVP-treated rats. CCI, chronic constriction injury; N, naive; V, vehicle; NVP, NVP CXCR2 20. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31616413), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-141_rabbit-polyclonal-gfap-antibody-310202415371927.jpg)
![Immunocytochemistry/ Immunofluorescence: GFAP Antibody [NB300-141] - Increased astrocyte activation in IL-1 beta -stimulated two-week old offspring is reduced by maternal LB supplementation. Representative images of fluorescence microscopy of claudin-5+ (location of the brain capillaries, red), GFAP+ astrocyte (green), & DAPI (nuclei, blue). Three to five sections per mouse were examined & at least three mice were examined in each group. Stronger than control SPF GFAP staining was observed around the blood vessel (see arrow) after IL-1 beta insult. Maternal supplemented group (LB) with or without postnatal insult had GFAP levels similar to the control group indicating that LB supplementation prevented astrocyte activation around the BBB endothelium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32424168), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-141_rabbit-polyclonal-gfap-antibody-310202415395936.jpg)
![Immunocytochemistry/ Immunofluorescence: GFAP Antibody [NB300-141] - Glial cells density is differently modulated during AD progression.a Retinal slices were immunolabeled with anti-GFAP antibody (green) & Hoechst for nuclei visualization (blue) at different ages of 3xTg-AD & non-Tg mice & density of GFAP signal was quantified as shown in b (**p < 0.01 pre vs early; n = 16 fields/four slices for each condition; two-way ANOVA, Holm-Sidak; ##p < 0.01 for comparison with age-matched non-Tg mice, two-way ANOVA, Holm-Sidak). c Representative multiarea image of retinal slice immunolabeled with anti-Iba1 antibody (green) & Hoechst for nuclei visualization (blue); density of Iba1+ cells was quantified as shown in d (**p < 0.01 vs 3xTg-AD pre; ##p < 0.01 vs age-matched non-Tg mice, n = 16 fields/four slices for each condition, two-way ANOVA, Holm-Sidak method for multiple comparison) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29880901), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-141_rabbit-polyclonal-gfap-antibody-310202416205151.jpg)
![Immunohistochemistry-Paraffin: GAP-43 Antibody [NB300-143] - Review image from confirmed customer on mouse E15.5 paraffin sections.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunohistochemistry-Paraffin-NB300-143-img0019.jpg "Immunohistochemistry-Paraffin: GAP-43 Antibody [NB300-143] - Review image from confirmed customer on mouse E15.5 paraffin sections.")
![Western Blot: GAP-43 Antibody [NB300-143] - Different tissue and cell lysates using rabbit pAb to GAP43, dilution 1:20,000 in green: [1] protein standard (red), [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord, [6] SH-SY5Y cells, [7] C6 cells. Single band at 43 kDa mark corresponds to GAP43 protein. The GAP43 protein is detected only in the lysates of neuronal origin. C6 cells are a rat glioma cell line and do not express GAP43 protein](http://images.novusbio.com/fullsize/GAP-43-Antibody-Western-Blot-NB300-143-img0022.jpg)
![Immunohistochemistry: GAP-43 Antibody [NB300-143] - Representative images of immunohistological staining (brown) of OMP-positive (OMP+) cells, GAP43+ immature ORNs. Tissue sections were counterstained with the nuclear dye hematoxylin (blue). Numbers of SOX2+ ORN progenitors and Ki67+ actively proliferating cells per mm of the basal layer and OMP+ mature ORNs, GAP43+ immature ORNs, and Cas3+ apoptotic cells per mm of the OE in saline or rhIGF-1-treated mice. Open circles, rectangles, and triangles represent the values for each mouse in the saline, low-IGF-1, and high-IGF-1 treated groups (each n = 6), respectively. Image collected and cropped by Citeab from the following publication (Dose-Dependent Effects of Insulin-Like Growth Factor 1 in the Aged Olfactory Epithelium. Front Aging Neurosci (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunohistochemistry-NB300-143-img0024.jpg)
![Immunohistochemistry-Paraffin: GAP-43 Antibody [NB300-143] - Posterior MOE sections at approximately the same region where EOG was recorded were obtained from control and Skn-1a-/- mice exposed to either water or chemicals for 2 wks. The sections were immunoreacted with antibodies against GAP43 and OMP and stained with DAPI. Confocal images were taken from olfactory turbinate II. Similar morphology and marker expression were found in four groups of mice, indicating there was no obvious tissue damage in both control and Skn-1a-/- mice after chemical exposure in the posterior MOE regions where EOG recordings were performed. Scale bar: 50 um. Image collected and cropped by CiteAb from the following publication (//eneuro.sfn.org/lookup/doi/10.1523/ENEURO.0135-17.2017), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunohistochemistry-Paraffin-NB300-143-img0023.jpg)
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody [NB300-143] - Cortical neuron-glial cell culture from E20 rat stained with rabbit pAb to GAP43, dilution 1:2,000 in green, and costained with mouse mAb to vimentin, dilution 1:2,000, in red. Blue: DAPI staining of nuclear DNA. GAP43 antibody labels protein expressed in the axonal membrane of neuronal cells, while vimentin antibody stains intermediate filaments in fibroblasts and other non-neuronal cells.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunocytochemistry-Immunofluorescence-NB300-143-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody [NB300-143] - Rat E18 mixed neuron/glia cultures with rabbit GAP43 (red) and 5B10, mouse monoclonal to MAP-tau (green).](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunocytochemistry-Immunofluorescence-NB300-143-img0018.jpg)
![Western Blot: GAP-43 Antibody [NB300-143] - Western blots of homogenate of cow cerebellum stained with RPCA-GAP-43 . A prominent band running at ~43kDa represents the full length GAP-43.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Western-Blot-NB300-143-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody [NB300-143] - Immunofluorescence of GAP-43 (green), a molecular marker of neurite outgrowth, demonstrates intense staining in overexpressing wild-type PS-1 (E) PC-12 cells. (Teo, et al, 2005)](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunocytochemistry-Immunofluorescence-NB300-143-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: GAP-43 Antibody [NB300-143] - Mixed neuron-glial cultures stained with RPCA-GAP43 (red), blue is DNA staining.](http://images.novusbio.com/fullsize/GAP-43-Antibody-Immunocytochemistry-Immunofluorescence-NB300-143-img0017.jpg)
![Western Blot: GAP-43 Antibody [NB300-143] - Silencing TFAP4 induces neuroblastoma cell differentiation. a Morphology of neuroblastoma cells after silencing TFAP4. Cells were grown in culture for 8 days, with 1 μg/ml doxycycline (shRNA induced) or without doxycycline. b Neurites # per field, & neurite length (pixels) were quantified with or without doxycycline. Mean ± std dev. *, P < 0.05; **, P < 0.01, ****, P < 0.0001. cGAP43 expression level (qRT-PCR) & protein level (western blot) in neuroblastoma cells. Gene expression was measured by quantitative PCR 4 days after induction of shRNA against TFAP4. Protein samples for western blot were collected from MYCN-amplified cells that were cultured with or without doxycycline (1 μg/ml) for 6 days Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29880876), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-143_rabbit-polyclonal-gap-43-antibody-310202415384199.jpg)
![Immunocytochemistry/ Immunofluorescence: GAP-43 Antibody [NB300-143] - LAMP1 increases in SDC-null corneas 14 days after trephine wound. Representative 3D images rotated to generate cross-sectional views show the localization of GAP43 (green), beta III tubulin (red), & LAMP1 (blue) in WT (top) & SDC1-null (bottom) corneas. These images show staining within a 0.5-μm cross-sections. Data indicate that axon fragments are being degraded (arrows). Representative INTs (*) & SBNs (#) have been highlighted & enlarged 3-fold. When LAMP1 expression within apical & basal cell layers 14 days after trephine injury is quantified & compared with unwounded controls (Fig. 2B), LAMP1 increases over 3-fold in SDC1-null corneas but remains the same in WT corneas. Scale bar: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28973369), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-143_rabbit-polyclonal-gap-43-antibody-310202415334931.jpg)
![Western Blot: GAP-43 Antibody [NB300-143] - Obesity & diabetes led to white adipose tissue neuropathy.The BTBR ob/ob (MUT) model of obesity & diabetes was compared to BTBR +/+ wild-type (WT) for body weight measurements (a), & adiposity (b). Body & tissue weight data were analyzed by two-tailed Student’s t-test. Von Frey tactile allodynia analysis was performed on MUT & WT animals to determine onset of peripheral neuropathy (c). Von Frey data was analyzed by ANOVA with Sidak’s post hoc test. For (a-c), all males; WT N = 8, 12–20 weeks old; MUT N = 6, 12–24 weeks old. Protein levels of PGP9.5 (d), as well as TH (e) in inguinal scWAT of the MUT & WT mice were measured by western blotting. For (e), lane 5 was excluded from analyses due to uneven resolution of housekeeper. For (d-e), all males; WT N = 5, 12–20 weeks old & MUT N = 4, 12–20 weeks old. Protein expression of PGP9.5 (f), TH (g), PSD95 (h), & GAP43 (i) in inguinal scWAT of 12–25 weeks old WT, 12 week old MUT & 24–28 week old MUT was measured by western blotting. All males, N = 3 per group. Western blot data were normalized to either beta -Tubulin or Cyclophilin B, band intensity were quantified in Image J, & analyzed by two-tailed Student’s t-test. Error bars are SEMs. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31509546), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-143_rabbit-polyclonal-gap-43-antibody-310202416212375.jpg)
![Immunocytochemistry/ Immunofluorescence: GAP-43 Antibody [NB300-143] - Intraepithelial nerve terminals extension into the apical most cell layers increases in SDC1-null corneas after trephine injury. Representative 3D images rotated to generate cross-sectional views show the localization of beta III tubulin (red) & GAP43 (green) at 4, 14, & 28 days after trephine wounding in WT & SDC1-null corneas. Punctate GAP43 is increased within the epithelium in SDC1-null compared with WT corneas at 14 days (*). beta III tubulin+ & GAP43+ INTs in the apical most cell layers were quantified as a function of time after trephine injury & normalized relative to control (presented in Fig. 2A). Asterisks within bars indicate differences that are significant relative to unwounded controls; asterisks between bars indicate significant differences between time points. In WT corneas, the numbers of beta III tubulin+ & GAP43+ INTs extending apically decrease relative to controls at 28 days for beta III tubulin+ INTs & at 4 & 28 days for GAP43+ INTS, in SDC1-null corneas, both beta III tubulin+ & GAP43+ INTs increase at all time points assessed. Scale bar: 25 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28973369), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-143_rabbit-polyclonal-gap-43-antibody-310202416212312.jpg)
![Immunocytochemistry/ Immunofluorescence: GAP-43 Antibody [NB300-143] - Differences in INTs & LAMP1 localization in WT & SDC1-null adult corneas. Representative high-resolution confocal 3D images rotated as indicated in the cartoon to the left were used to generate cross sectional views to show the localization of beta III tubulin (red) & GAP43 (green) in intraepithelial nerve terminals in control WT & SDC1-null corneas. The images shown in (A) project through 135 μm of tissue, images in (B) project through 0.5 μm of tissue. (A) Intraepithelial corneal nerves are shown to be linear, arise from the subbasal nerves (SBNs), & project apically. Quantitation of beta III tubulin & GAP43 within apical & basal layers of the corneal epithelium reveals that WT corneas have significantly more INTs in both basal & apical cell layers compared with SDC1-null corneas. Although SDC1-null corneas have fewer INTs, they are equally capable of extending toward the apical most cell layers. (B) In the 0.5-μm cross-sectional slices through the tissue, INTs appear discontinuous. In addition to beta III tubulin & GAP43, LAMP1 is shown in blue. LAMP1 is a lysosomal marker; co-localization of GAP43 and/or beta III tubulin within corneal epithelial cell lysosomes indicate that axon fragments have been phagocytozed & are being degraded (arrows). The sites indicated by the asterisks have been digitally enlarged 3-fold. LAMP1 was quantified in WT & SDC1-null corneas. Data show that cells within the apical layers express more LAMP1 compared with basal cells in both genotypes of mice. In addition, WT corneas express 2- to 3-fold more LAMP1 in apical & basal layers compared with SDC1-null corneas. Scale bar: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28973369), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-143_rabbit-polyclonal-gap-43-antibody-31020241620512.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Subcellular localization of BEST1 and surface Ca2+-dependent Cl- current in patient-derived iPSC-RPEs. Western blots show similar BEST1 expression levels in WT and patient-derived iPSC-RPEs. Each sample was from one cell lysis (BEST1 and beta-actin, RPE65 and CRALBP were on two gels, respectively). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29914), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Western-Blot-NB100-355-img0013.jpg "Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Subcellular localization of BEST1 and surface Ca2+-dependent Cl- current in patient-derived iPSC-RPEs. Western blots show similar BEST1 expression levels in WT and patient-derived iPSC-RPEs. Each sample was from one cell lysis (BEST1 and beta-actin, RPE65 and CRALBP were on two gels, respectively). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29914), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Expression of eye-specific markers in the induced eye-like structures induced from lignin-added ES cells. (a) Higher-magnification image of the RPE like structure induced from ESCs after 12-day culture. (b) Immunostaining of eye- like structures. Eye- like structures induced from ESCs after 12-day culture were stained with antibodies against RPE65 (red) and nuclei were stained with DAPI solution (blue). Scale bar: a = 50 um, b,d = 200 um, c,e = 100 um. PLoS One. 2013 Jun 21;8(6):e66376. doi: 10.1371/journal.pone.0066376.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-355-img0014.jpg)
![Immunohistochemistry-Paraffin: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Analysis of FFPE human glioblastoma tissue section using 1:500 dilution of RPE65 [401.8B11.3D9] antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems).](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-Paraffin-NB100-355-img0012.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - WB analysis of RPE65 in 20ug lysate of COS7 cells expressing recombinant Human RPE65 (Lane 1) and 5ug of Bovine retinal pigment epithelium membrane fraction (Lane 2). Blot processed for detection with alkaline phosphatase conjugated goat-anti Mouse IgG secondary antibody and NBT/BCIP substrate.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Western-Blot-NB100-355-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - ICC-IF analysis of cultured ARPE19 cells, a spontaneously arising human retinal pigment epithelia cell line - 10 minutes fixation in 4% PFA, 10 minutes permeabilization in PBS containing 0.2% Triton X-100 (PBS-T), 1 hour blocking in 10% normal goat serum containing 1% BSA in PBS-T, 1:100 primary antibody dilution in PBS, ON 4C incubation.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-355-img0006.jpg)
![Immunohistochemistry-Frozen: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Staining of RPE65 in a cryosection of mouse retina tissue using RPE65 antibody (clone 401.8B11.3D9).](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-Frozen-NB100-355-img0007.jpg)
![Immunohistochemistry: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Zebrafish brain ventricular area labeled with mouse anti-RPE65 (1:100). This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Immunohistochemistry-NB100-355-img0011.jpg)
![Simple Western: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - iPSC-RPE from all donors express RPE marker proteins. iPSC-RPE from the patient, the patients mom, the patients dad, and the three unrelated, unaffected controls all expressed RPE65. The negative control (iPSCs) had no detectable RPE65 protein expression. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29540715/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Simple-Western-NB100-355-img0016.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Immunoblotting showing the expression of RPE-specific proteins BEST1 (NB300-164), RPE65 (NB100-355), CRALBP, and the loading control beta-Actin in iPSC-RPE cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta-Actin, and RPE65 + CRALBP, respectively. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPE65-Antibody-401-8B11-3D9-BSA-Free-Knockout-Validated-NB100-355-img0015.jpg)
![Western Blot: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - Expression of RPE-specific marker proteins in hPSC-RPE & iPSC-RPE cells.(a–b) Immunoblotting showing the expression of RPE-specific proteins BEST1, RPE65, CRALBP, & the loading control beta -Actin in hPSC-RPE (a) & iPSC-RPE (b) cells. Two gels/blots in the same panel were prepared from the same cell lysate of each PSC-RPE to detect BEST1 + beta -Actin, & RPE65 + CRALBP, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34061021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241539592.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-310202415541976.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241682152.jpg)
![Immunocytochemistry/ Immunofluorescence: RPE65 Antibody (401.8B11.3D9) - BSA Free [NB100-355] - BMP5 induces ectopic RPE development in the central NR at optic cup stages. (A,B) Peripheral, untreated chick eye at E8 showing pigmentation & MITF expression being restricted to the outer layer of the eye. The arrowheads indicate the peripheral NR. (C-F) Higher magnification of the central chick eye at E8 showing the pigmented RPE, where RPE65 protein is detected (arrows). Faint Wnt2b & strong Vsx2 expression is detected in the central NR. The arrows indicate the RPE. (G,H) Following BMP5 application at E3.5/4, the NR detached (arrowhead) & MITF protein is now detected in the central NR (cNR). Note that a part of the cNR has RPE-like morphology (eRPE). (I-L) Higher magnification images of the eRPE. Ectopic pigment granulae, RPE65 protein & strong Wnt2b expression are detected in this region, whereas Vsx2 expression is downregulated (arrowheads). (M-O) Untreated chick eye at E8 showing pigmentation & MITF (arrow) & VSX2 protein distribution, restricted to the RPE & NR, respectively. (P-R) Following BMP5 application at E3.5/4, ectopic pigmentation & nuclear MITF protein are detected in the inner optic cup (arrowheads), whereas VSX2 protein is only weakly or not detected. The arrows indicate the RPE. (S) Graphical representation of the average thickness of the inner layer of the untreated (control) & BMP5-treated eye at E8. All expression pattern studies included n≥5. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28546339), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-355_mouse-monoclonal-rpe65-antibody-401-8b11-3d9-31020241682148.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib reduced TNBC cell migration & targeted p-STAT3/VEGF-A signaling.(A) Chemical structure of regorafenib. (B,C), Transwell assay (B) & wound-healing assay (C) were performed in TNBC cell lines after regorafenib treatment for 24 h. *p 160) or low VEGF-A (H score < = 160) levels for the indicated time of follow up. Chi-square test indicated a significant difference between VEGF-A high (N = 21) & low (N = 76) patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-3102024155374.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![Analysis of a FFPE tissue section of human liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-1211202510571.jpg)
![Analysis of a FFPE tissue section of mouse liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-12112025105832.jpg)
![Western Blot: Tyrosine Hydroxylase Antibody [NB300-110] - Analysis of rat caudate lysate showing specific immunolabeling of the ~60 kDa tyrosine hydroxylase protein.](http://images.novusbio.com/fullsize/Tyrosine-Hydroxylase-Antibody-Western-Blot-NB300-110-img0006.jpg "Western Blot: Tyrosine Hydroxylase Antibody [NB300-110] - Analysis of rat caudate lysate showing specific immunolabeling of the ~60 kDa tyrosine hydroxylase protein.")
![Western Blot: Tyrosine Hydroxylase Antibody [NB300-110] - Mice were injected with PBS (control group) or the dopaminergic neurotoxin MPTP. There is low concentration of TH in the striatum of mouse injected with MPTP. 30 ug total protein per lane. Antibody at 1:3000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Tyrosine-Hydroxylase-Antibody-Western-Blot-NB300-110-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Alpha-Synuclein overexpression or intracerebral seeding impacts the dopaminergic system. Increased levels of ser129-phosphosynuclein in the substantia nigra (arrows) indicate alpha-syn stress in PFF injected animals. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30050065/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Tyrosine Hydroxylase Antibody-Immunocytochemistry-Immunofluorescence-NB300-110-img0013.jpg)
![Immunohistochemistry: Tyrosine Hydroxylase Antibody [NB300-110] - Mouse cryo-sections. Antibody at 1:500. Secondary antibody: dk-anti-sp Alexa Fluor488 at 1:500; 1 h. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Tyrosine-Hydroxylase-Antibody-Immunohistochemistry-NB300-110-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Nmnat by itself does not protect dopaminergic neurons from MPP+ toxicity. Similar transduction efficiencies of the different lentiviruses were confirmed by quantifying the number of TH+ and GFP+ cells following transduction of dopaminergic cultures. Quantification of TH+ cell bodies and (E) TH+ neurites show that only WldS-transduced cultures protected neurites against MPP+. Data are normalized to control cultures and denote the mean +/- SEM of representative determinations made in three separate cultures. *p 99.8% posterior probability); green, expressed above baseline in human (>99.8% posterior probability); gray, not expressed above baseline.(F) Validation of LMO3 expression by immunohistochemistry in a subset of TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm).(G) Validation of BNC2 expression by immunohistochemistry in TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm). Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S0092867416313095), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-310202416205145.jpg)
![Immunocytochemistry/ Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Developmental song exposure & social context affect cFOS expression in TH neurons of the caudal VTA. Sagittal drawings (A,C) & photomicrographs of tyrosine hydroxylase (TH; green label) expression (B,D) in the ventral tegmental area (VTA) & periaqueductal gray (PAG; panels A,B), & the substantia nigra pars compacta (SNc) & locus coeruleus (LC; panels C,D). (E) Examples of co-localized expression of TH (green) & cFOS (red) in the caudal VTA of a normally-reared bird that heard silence (left panel), UD song (middle panel; UD song) & FD song (FD; right panel). White arrows indicate examples of colocalized expression. (F) Percent of TH neurons co-localized with cFOS in the caudal VTA (cVTA), rostral VTA (rVTA) & SNc. Box-and-whisker plots for normally-reared (yellow colors) & song-naïve (green colors) hearing UD (UD; lighter colors) or female-directed (FD; darker colors) songs. Each box spans the interquartile range, horizontal white lines indicate the median & whiskers show the minima & maxima. Levels of cFOS expression in TH neurons for silence controls are plotted as the mean (gray dashed line) +/− standard error (gray boxes). *Indicates a significant difference at p 99.8% posterior probability); green, expressed above baseline in human (>99.8% posterior probability); gray, not expressed above baseline.(F) Validation of LMO3 expression by immunohistochemistry in a subset of TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm).(G) Validation of BNC2 expression by immunohistochemistry in TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm). Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S0092867416313095), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-31020241621840.jpg)
![Immunocytochemistry/ Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Conversion of hNES cells into hPRogFPM & their differentiation into midbrain dopaminergic neurons. a Schematic representation of the conversion & differentiation protocols. b, cRT-qPCR analysis at day 8, showing the expression of midbrain-hindbrain TFs, such as OTX2, GBX2, LMX1A, & FOXA2 (b), as well as the dopaminergic neuron markers, NR4A2, TH, SLC18A22, & SLC6A3 (c). d Immunocytochemistry analysis of the presence of OTX2 & TH in control unconverted NES cultures, compared with NES cells converted with SAF+Dkk1 & differentiated until day 8. e, f Percentage of OTX2+ & TH+ cells in the conditions in d. P = 0.02673 (e), P = 0.03233 (f), n = 3. g–i Expression of the key midbrain TFs, LMX1A, NR4A2, & PBX1, in TH+cells derived from SAI2-NES cells after conversion & differentiation. j, k TH+ cells express the mature neuronal marker, MAP2 (j), & some acquire mature neuronal morphologies, with long processes & varicosities at day 8 (k). Scale 50μm. Box plots (b, c, e, f): Center line, median; hinges, 25% & 75% quartiles; whiskers, 1.5 interquartile range. Statistics: (b, c) ANOVA, followed by pair-wise t-test with Bonferroni correction for multiple testing. (e, f). Two sample t-test; *P ≤ 0,05; **P ≤ 0,01; ***P ≤ 0,001. N = 3 (GBX2, FOXA2, TH, SLC6A3), n = 4 (LMX1A, OTX2, NR4A2, SLC18A2) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968757), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-31020241621231.jpg)
![Immunocytochemistry/ Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Conversion of hNES cells into hPRogFPM & their differentiation into midbrain dopaminergic neurons. a Schematic representation of the conversion & differentiation protocols. b, cRT-qPCR analysis at day 8, showing the expression of midbrain-hindbrain TFs, such as OTX2, GBX2, LMX1A, & FOXA2 (b), as well as the dopaminergic neuron markers, NR4A2, TH, SLC18A22, & SLC6A3 (c). d Immunocytochemistry analysis of the presence of OTX2 & TH in control unconverted NES cultures, compared with NES cells converted with SAF+Dkk1 & differentiated until day 8. e, f Percentage of OTX2+ & TH+ cells in the conditions in d. P = 0.02673 (e), P = 0.03233 (f), n = 3. g–i Expression of the key midbrain TFs, LMX1A, NR4A2, & PBX1, in TH+cells derived from SAI2-NES cells after conversion & differentiation. j, k TH+ cells express the mature neuronal marker, MAP2 (j), & some acquire mature neuronal morphologies, with long processes & varicosities at day 8 (k). Scale 50μm. Box plots (b, c, e, f): Center line, median; hinges, 25% & 75% quartiles; whiskers, 1.5 interquartile range. Statistics: (b, c) ANOVA, followed by pair-wise t-test with Bonferroni correction for multiple testing. (e, f). Two sample t-test; *P ≤ 0,05; **P ≤ 0,01; ***P ≤ 0,001. N = 3 (GBX2, FOXA2, TH, SLC6A3), n = 4 (LMX1A, OTX2, NR4A2, SLC18A2) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968757), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-31020241621841.jpg)
![Immunocytochemistry/ Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - Comparison of Mouse & Human Dopaminergic Neuronal Development(A) WNT1 compartments marking lateral population of the floor plate in human & mouse tissue (scale bar, 100 μm).(B) Bar plot of cell types of the human & mouse dopaminergic lineage, showing the expression of key genes. Bars show average mRNA expression, scaled to the absolute molecule counts indicated on the right axis. Error bars show SEM.(C) Validation of mNbM by in situ hybridization for Igfbpl1 & Nhlh1 (scale bar, 50 μm).(D) Neuroblasts in human & mouse ventral midbrain (scale bar, 100 μm; magnification, 20 μm).(E) Selected genes showing similar (left) or distinct (right) expression in mouse & human ventral midbrain. Blue, expressed above baseline in mouse (>99.8% posterior probability); green, expressed above baseline in human (>99.8% posterior probability); gray, not expressed above baseline.(F) Validation of LMO3 expression by immunohistochemistry in a subset of TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm).(G) Validation of BNC2 expression by immunohistochemistry in TH+ neurons in the E18.5 mouse ventral midbrain (scale bar left, 100 μm; right, 20 μm). Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S0092867416313095), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-31020241621827.jpg)
![Immunocytochemistry/ Immunofluorescence: Tyrosine Hydroxylase Antibody [NB300-110] - alpha -Synuclein overexpression or intracerebral seeding impacts the dopaminergic system.a–c Intranigral injection of AAV2/6 serotype expressing human alpha -syn (h-syn) results in increased protein expression paralleled by reduction in tyrosine hydroxylase (TH) levels. (d) h-syn is also expressed in dopaminergic cell bodies (arrows). e Unbiased stereological counts demonstrate a reduction in nigral dopaminergic cell bodies. f, g Intracranial injection of alpha -syn pre-formed fibrils (PFF) causes striatal dopaminergic denervation as evidenced by a reduction in TH immunoreactivity. h Increased levels of ser129-phosphosynuclein in the substantia nigra (arrows) indicate alpha -syn stress in PFF injected animals. i Unbiased stereological counts showing a decrease in dopaminergic cell bodies in the substantia nigra. Scale bars: 1 mm in a, b 50 μm in d. (**p < 0.01; ***p < 0.001; Student’s t test). All bar graphs show mean + /− s.e.m Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30050065), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-110_sheep-polyclonal-tyrosine-hydroxylase-antibody-310202416212352.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0017.jpg "Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0019.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in transfected and native mouse cell lysate. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0003.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in human liver and spleen tissues. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0004.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0018.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: ZEB1 Antibody [NBP1-05987] - Detection of human ZEB1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-ZEB1 antibody NBP1-05987 used for IP at 3 ug per reaction. ZEB1 was also immunoprecipitated by another rabbit anti-ZEB1 antibody. For blotting immunoprecipitated ZEB1, NBP1-05987 was used at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunoprecipitation-NBP1-05987-img0013.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415382430.jpg)
![Immunohistochemistry: ZEB1 Antibody [NBP1-05987] - Immunohistochemical staining results of EMT regulators in HG‐PanIN: SNAIL, SLUG, TWIST1, & ZEB1. We categorized & defined three grades: grade 0, <10% positive staining; grade 1, 10%‐50% positive; grade 2, 50%< positive Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30791220), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415291996.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Location of Zeb1 proteins in mEC lines (mESC, mEB, GC1, & P19). Immunofluorescence analysis was used to determine localization of Zeb1 in mESC, mEB, GC1, & P19 using a Zeb1 antibody (red). Cell nuclei were labeled with Hoechst 33342 (blue). The scale for the measurement bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241539712.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241529198.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304286.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Zeb1 expression in mESCs, mEB, GC1, & P19. (a) Zeb1 mRNA expression detected by real-time qPCR in mESC, mEB, GC1, & P19 (P < 0.001, data presented as mean value ± SD). (b) Zeb1 protein expression examined by western blot in mESC, mEB, GC1, & P19. Each experiment was performed in triplicate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304288.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241528450.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Correlation of the expression of ZEB1 & IL‐6 & other cytokines in various cancers. (A) Correlation analysis of the expression of ZEB1 & cytokines in breast cancer cell lines using data obtained from the Cancer Cell Line Encyclopedia (CCLE). Breast cancer cell lines were selected for the analysis, & each dot represents a cell line. Affymetrix microarray probe IDs for IL6 & IL8 are shown after the gene symbols on the y‐axis. RMA, robust multiarray average. (B) Representative results obtained from the tissue array analysis in Fig. S3. The top panel shows a case that was positive for both nuclear ZEB1 staining (green) & whole‐cell IL‐6 staining (red); scores = 4. The bottom panel shows a case that was negative for both ZEB1 & IL‐6; scores = 1. The samples were counterstained with DAPI to show cell density in the spot. Original magnification: 20 ×. (C) Kaplan–Meier survival curves of breast & lung cancer patients obtained from a public meta‐analysis database & Kaplan–Meier plotter (Gyorffy et al., 2010, 2013). The probability of overall survival of patients as split by median IL6 & IL8 expression is shown. Red: IL6 & IL8 high expression group; black: IL6 & IL8 low expression group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28618162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616091.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616017.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616067.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Vimentin & ZEB1 protein levels are regulated by OVOL1 & OVOL2 in a human SCC cell line. (A) Relative protein expression levels of OVOL1 & OVOL2 in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 48 h. (Left) Representative blot images & (right) relative expression levels calculated from three independent experiments. (B) Relative protein expression levels of vimentin, ZEB1, & E-cadherin in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 72 h. (Upper) representative blot images & (lower) relative protein expression levels calculated from three independent experiments. Mann–Whitney U-test; error bars represent mean ± standard deviation. Protein expressions are relative to those of beta -actin as a reference. The control siRNA value was set to 1. p-values < 0.05 were assumed to indicate a statistically significant difference; * p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32106476), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175281.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416182642.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - FGFR1 siRNAs attenuate the malignant phenotypes of cancer cells.(A) mRNA from TSU cells transfected with siRNAs against FGFR1 (siFGFR1) were subjected to conventional RT-PCR to determine the levels of endogenous FGFR1. (B, C, D) After transfection with siFGFR1 in TSU cells, phosphorylation of ERK1/2 (p-ERK1/2) (B), ZEB1 levels (C), & cell morphology (D) were determined. (E) TSU cells transfected with siFGFR1 were subjected to immunofluorescence analyses. Low magnification, 40×; high magnification, 80×. (F, G, H, I) After either treatment with SU5402 or transfection with siFGFR1 in TSU & HOC313 cells, the number of cells & invasive properties were determined under serum-free culture conditions. (J & K) After transfection with siFGFR1c in TSU & HOC313 cells, invasive & migratory properties were determined under serum-free culture conditions in TSU & HOC313 cells, respectively. siNC, non-specific control siRNA. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results were obtained from at least three independent experiments. p values were determined by Student’s t-test. *p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175241.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416163718.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Nav1.4 protein levels are decreased in muscles from mouse models of SMA. (A) Immunoblot analysis using muscle lysate from P2, P5, P9, & P21 wild type mice. Nav1.4 protein levels increase during postnatal muscle development & form the predominant sodium channel expressed in mature skeletal muscle. GAPDH served as a loading control (N = 3). (B) Representative immunoblot with quantification, showing a decrease in levels of sodium channel Nav1.4 & Nav1.5 in P5 Smn-/-;SMN2 hindlimb muscle compared with controls (N = 3). (C) Quantification of immunoblot analyses in P21 Smn2B/- & control hindlimb muscles revealed a decrease in Nav1.4 levels. Early in postnatal muscle development, the Nav1.5 sodium channel isoform is the most predominant. In P21 Smn2B/- mice, the protein levels of Nav1.5 are higher than in controls (N = 3). (D) The protein level of the Nav1.4 positive regulator, NF1, is not altered in muscles from P21 Smn2B/- mice. Similarly, no change was detected in the protein levels of the Nav1.4 repressor ZEB. (E) Expression of sodium channel Nav1.4 in control sham & denervated samples 1 & 7 days post-denervation was assessed by immunoblot (N = 3). A decrease in the levels of Nav1.4 in muscle was noted at 7 days post-denervation. *, P < 0.05; **, P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24119341), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241617522.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - T47D cells form functional 3D spheroids in a scaffold-free system. Sections of 3D microtissues grown for 12 days were incubated with DAPI and an antibody against Ki67 (green) to stain proliferative cells analyzed by fluorescence microscopy. Nuclei were visualized with DAPI (blue). Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.630), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunocytochemistry-Immunofluorescence-NB600-1252-img0008.jpg "Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - T47D cells form functional 3D spheroids in a scaffold-free system. Sections of 3D microtissues grown for 12 days were incubated with DAPI and an antibody against Ki67 (green) to stain proliferative cells analyzed by fluorescence microscopy. Nuclei were visualized with DAPI (blue). Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.630), licensed under a CC-BY license.")
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - PW-12 is efficacious in an orthotopic flank tumor model of MYCN-amplified medulloblastoma. Mice were implanted with 6 x 106 SmoWT medulloblastoma cells in the hindflank. Animals were treated for 7 days with 25 mg/kg of PW-12 (n = 5) or vehicle alone (n = 5). Histology on H&E stain is consistent with medulloblastoma (H&E, 20x). Tumor cell proliferation (Ki67, 40x) was decreased, apoptosis (cleaved-caspase-3, 40x) increased, MYCN (20x) expression downregulated, and vascularity decreased in PW-12 treated tumors as confirmed by histology and cell quantification for apoptosis and cell proliferation. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/Cancer_Molecular_Targets_and_Therapeutics/10.3389/fonc.2015.00111/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-NB600-1252-img0007.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Formalin fixed paraffin embedded human tonsil stained with Ki-67 antibody.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-Paraffin-NB600-1252-img0001.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Ki-67/MKI67 Antibody (SP6) [NB600-1252] - Formalin fixed paraffin embedded human tonsil stained with Ki-67 antibody.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-Paraffin-NB600-1252-img0002.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Paraffin-embedded alcohol fixed rat spleen tissue (20x). Antigen retrieval pH 9. Ki67 dilution 1:100 incubation ON 4C. This image was submitted via customer review.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-NB600-1252-img0005.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - PW-12 is efficacious in a GEM model of MYCN-amplified neuroblastoma. Tumor-bearing TH-MYCN mice were treated for 14 days with either 25 mg/kg of PW-12 (n = 3) or vehicle alone (n = 3). Histology for Ki67 and c-Caspase 3 shows increase in apoptosis and decrease in proliferation in treated tumors. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/Cancer_Molecular_Targets_and_Therapeutics/10.3389/fonc.2015.00111/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-NB600-1252-img0006.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Ki-67/MKI67 Antibody (SP6) [NB600-1252] - Ki67 staining in mouse thyroid tissue at pre-tumor stage (green). Dilution is 1:100. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-SP6-Unpurified-Immunohistochemistry-NB600-1252-img0003.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Ki-67 (NB600-1252) immunoreactivity in an FFPE section of mouse small intestine. Primary antibody was diluted 1:100 and left on sections for 1h at room temperature. Secondary antibody was Horse Anti-Rabbit HRP. Image from verified customer review.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-immunohistochemistry-paraffin-204202311437.jpg)
![Immunohistochemistry-Paraffin: Rabbit Monoclonal Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Image depicting Ki67/MKI67 immunoreactivity in a FFPE section of human tonsil. NB600-1252 was diluted 1-100 and left on tissue sections for 30m at room temperature. Secondary was horse anti rabbit HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-immunohistochemistry-paraffin-2442024135233..png)
![Immunohistochemistry-Paraffin: Rabbit Monoclonal Ki67/MKI67 Antibody (SP6) - Unpurified [IMGENEX: IMG-80336] [NB600-1252] - Images depicting Ki67/MKI67 immunoreactivity in FFPE sections of canine cecum and skin. NB600-1252 was diluted 1-100 and left on tissue sections for 30m at room temperature. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-imgenex-img-80336-immunohistochemistry-paraffin-1052024152017..jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Immunohistochemistry of tissue slices treated with trastuzumab & docetaxel. (Ki-67, arrows; A-C) & (cleaved caspase-3, arrows; D-F) were quantified by counting the number of positively stained cells in 4 fields of view at x40. Images are representative of untreated (A, D), trastuzumab at 100 µg/ml (B & E) & docetaxel at 100 nM (C & F). Images were digitally scanned ×40 (AlexaSoft X-PRO). Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/or.2015.4074), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202415371921.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - (A–C) Inflammatory cell infiltration & cell division in the nasal RM were evaluated using immunohistochemical staining (brown). Tissue sections were counterstained with the nuclear dye hematoxylin (blue). Representative immunohistochemical images of neutrophils (A), CD3+ lymphocytes (B), & Ki67+ dividing cells (C) (400× magnification), & comparative charts of cell counts in each group. *P < 0.01; **P < 0.01; ****P < 0.0001 (n = 6, one-way analysis of variance). OVA, ovalbumin; CSS, cigarette smoke solution. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32132898), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202415284528.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - In vivo anti-tumor effect of Y-TR1 in the NOD/SCID mouse xenograft model using CD26 positive MM cell line JMN. (A) Y-TR1 administered intraperitoneally 4 mg/kg/dose, three times per week, for a total of nine doses from day zero of subcutaneous inoculation of 1 × 107 JMN cells. Average estimated tumor volume on day 55 compared among three groups (control, YS110, Y-TR1, n = 10) w/ Fisher’s protected least protected difference multiple comparison test. Mean tumor volume of the Y-TR1 group significantly lower (* p < 0.05) than that of the control or YS110 group. Mean tumor volume of the YS110 group not significantly altered compared w/ the control. An experiment out of two w/ similar results is shown; (B) Y-TR1 administered intraperitoneally 8 mg/kg/dose, three times per week, for a total of nine doses. The average estimated tumor weight on day 42 compared among three groups (control, 14D10, YS110, Y-TR1, n = 10) w/ Fisher’s protected least protected difference multiple comparison test. Mean tumor weight of the YS110 or Y-TR1 groups significantly lower (* p < 0.05 or ** p < 0.025, respectively) than that of the control group. Mean tumor weight of the Y-TR1 group significantly lower (* p < 0.05) than that of the YS110 group. An experiment out of two w/ similar results is shown; (C) histological analysis of xenograft tumors of JMN cells. JMN-derived tumors show histopathology of sarcomatoid mesothelioma. (×20). a: Hematoxylin & eosin staining. b: Immunohistochemical staining w/ anti-human CD26 antibody revealed CD26 expression in tumor cells. c–e: MIB-1 (Ki67) staining showed a decreased number of MIB-1-positive cells in Y-TR1-treated tumors compared to IgG1- or YS110-treated tumors. Scale bar: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31398954), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202416165616.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - Representative images of immunohistological staining (brown) of OMP-positive (OMP+) cells (A), SOX2+ ORN progenitor cells (B), GAP43+ immature ORNs (C), Ki67+ proliferating cells (D), & cleaved Cas3+ apoptotic cells (E). Each cell except for many OMP+ cells is indicated by arrows. Tissue sections were counterstained with the nuclear dye hematoxylin (blue). Numbers of SOX2+ ORN progenitors & Ki67+ actively proliferating cells per mm of the basal layer & OMP+ mature ORNs, GAP43+ immature ORNs, & Cas3+ apoptotic cells per mm of the OE in saline or rhIGF-1-treated mice. Open circles, rectangles, & triangles represent the values for each mouse in the saline, low-IGF-1, & high-IGF-1 treated groups (each n = 6), respectively. The horizontal lines represent the mean value for each group. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; & ∗∗∗∗P < 0.0001 (one-way ANOVA). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30515092), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202416182632.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - (A) Serum immunoglobin E (IgE) levels of the control & cigarette smoke solution (CSS)-treated mice were determined by enzyme linked immunosorbent assay. (B) Representative images of Sirius red staining for eosinophils & periodic acid-Schiff & Alcian blue (PAS/AB) staining for goblet cells in the nasal RM of the control mice & mice treated with 10 doses of CSS (CSS 10). (C) Representative immunohistochemical images of neutrophils & Ki67+ dividing cells in the nasal RM (400× magnification), & comparative charts of Ki67+ cell counts (n = 6, Mann–Whitney U test). (D) Representative images of olfactory marker protein (OMP)+ mature olfactory receptor neurons (ORNs) in two different areas of the olfactory epithelium: the nasal septum & upper lateral area. There were no significant differences in the number of OMP+ mature ORNs between the control & CSS-treated mice (n = 6, Mann–Whitney U test). OVA, ovalbumin. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32132898), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202416173541.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody (SP6) - Unpurified [NB600-1252] - (A,B) Representative images of hematoxylin & eosin (H&E)-stained sections of the olfactory epithelium from young adult mice (A, 40× magnification; B, 400× magnification). A black line in (A) indicates the range for counting the number of each cell type. The box in (A) indicates the region of the olfactory epithelium shown at a representative higher magnification in (B). Differences in the number of OMP+ mature olfactory receptor neurons (ORNs) (C), SOX2+ ORN progenitors (D), Ki-67+ proliferating cells (E), GAP43+ immature ORNs (F), & cleaved Cas3+ apoptotic cells (G) in the OE were evaluated by immunohistological staining (brown). Tissue sections were counterstained with the nuclear dye hematoxylin (blue). Representative images (400× magnification) of tissues stained with antibodies against olfactory marker protein (OMP), SRY (sex determining region Y)-box 2 (SOX2), Ki-67 (antigen identified by monoclonal antibody Ki-67), growth associated protein 43 (GAP43), & cleaved caspase 3 (CAS3) are shown. The number of cells per mm of basal layer length (C–G) was counted manually. Data represent the mean ± SD. **P < 0.01 (n = 6, Mann–Whitney U-test). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fnagi.2018.00086/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1252_rabbit-monoclonal-ki67-mki67-antibody-sp6-unpurified-310202416161841.jpg)
![Immunocytochemistry/Immunofluorescence: SCP3/SYCP3 Antibody [NB300-232] - Chromosome spread for sycp3. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SCP3-SYCP3-Antibody-Immunocytochemistry-Immunofluorescence-NB300-232-img0013.jpg "Immunocytochemistry/Immunofluorescence: SCP3/SYCP3 Antibody [NB300-232] - Chromosome spread for sycp3. ICC/IF image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: SCP3/SYCP3 Antibody [NB300-232] - IHC analysis of a formalin fixed and paraffin embedded tissue section of Mouse testis using SCP3 antibody at 1:1000 dilution. The signal was detected using HRP-DAB detection method and the nuclei were counterstained with hematoxylin. The antibody generated a specific signal of SCP3 in the spermatogonial cells and the spermatocytes. The signal was strongest in the nuclei of spermatogonial cells.](http://images.novusbio.com/fullsize/SCP3-SYCP3-Antibody-Immunohistochemistry-Paraffin-NB300-232-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: SCP3/SYCP3 Antibody [NB300-232] - Exposure to DEHP impairs meiotic progression of oocytes from pachytene to diplotene. Immunolabeling of the oocyte chromosomes with anti-SYCP3 antibody (red) and Hoechst 33342 (blue). All experiments were repeated at least three times independently. (* P600 spermatocytes in each stage. b, c The immunostaining of SYCP3 in the testicular sections (b) & surface-spread chromatin preparations of Uhrf1 deletion & control mice (c); d the percentage of spermatocytes with abnormal SYCP3 location. e Double immunofluorescence of testicular spread preparations of the adult mice, SYCP3 (green) & SYCP1 (red). f The percentage of spermatocytes with abnormal SYCP1 location. Lep leptotene, Zyg zygotene, Pac pachytene, Dip diplotene. Data are presented as mean ± SEM of three mice. ***p ≤ 0.001. Scale bar, 25 μm in b, 5 μm in c, e. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32081844), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-31020241621832.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - Dynamic expression of germ cell markers in human fetal ovaries. (A) Histological sections of human ovaries at W10.5, W14, W17 & W21.5, immunostained for the early germ cell marker (nuclear) POU5F1 (red) & late germ cell marker (cytoplasmic) DDX4 (green). In zone 1, most germ cells are POU5F1+DDX4−/low; in zone 2 & 3, most germ cells are DDX4+. Several germ cells in zone 3 have developed into primordial follicles. Inserts are magnifications of the dotted boxes. (B) Histological sections of human ovaries at W10.5, W14, W17 & W21.5, immunostained for the meiotic markers H2AFX (red) & SYCP3 (green). Inserts are magnifications of the dotted boxes. Note the presence of autofluorescent red blood cells. Scale bars are 200 µm & in the magnified inserts 20 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26834021), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-31020241620376.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - CYP51 regulates the expression of the meiosis-specific cohesin subunits REC8 & STAG3. (A,B) RS21745 treatment decreased REC8 & STAG3 expression. Ovaries at 14.5 dpc were cultured with 10 μM RS21745 for 3 days in vitro. (A) Expression of the cohesin subunits following RS21745 treatment by qRT-PCR. All qRT-PCR values were normalized to beta -actin & were expressed as a relative ratio to the control; the means±s.e.m. of 3 values are shown. (B) Expression of REC8 & STAG3 following RS21745 treatment by western blotting GAPDH was used as internal reference. (C–F) Inhibition of CYP51 disturbed the distribution of both REC8 & STAG3 on the chromosomes. (C,E) In the control groups, REC8 & STAG3 expression was observed at high levels in zygotene oocytes. In the CYP51 inhibition groups, the cohesin signals were absent in zygotene cells. (D,F) The percentage of REC8-positive or STAG3-positive oocytes at the zygotene stage was recorded. Unidentified germ cells were not included in the analyses. Scale bars: 10 μm. The data are presented as the means±s.e.m. of 3–9 ovaries per group. Asterisk (*) denotes a statistically significant difference between the control & the treatment groups. ***P<0.001 (t-test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30420384), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-310202416212332.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - Induction of meiosis is compromised in the cortical germ cells of D17 embryos subject to oestrogen level alterations. (A) D17 (HH43) left gonad sections immunostained for gamma H2AX (green) & P63 (red); nuclei are counterstained with DAPI (blue). (B) Sections from the D17 (HH43) left gonad shown in A immunostained for gamma H2AX (green) & SYCP3 (red). ZW-WT, ZW wild type; ZW-Fa, ZW treated with fadrozole from D7-7.5 (HH31); ZW-E2, ZW treated with beta -oestradiol at D7-7.5; ZZ-E2, ZZ treated with beta -oestradiol at D7-7.5; ZW-Fa(sr), ZW, partially sex-reversed gonad, treated with fadrozole at D4; ZZ-E2(sr), ZZ, partially sex-reversed gonad, treated with beta -oestradiol at D4. All gonadal models have a cortical domain containing germ cells. In ZW-Fa ovary & ZW-E2 ovary, most cortical germ cells express SYCP3 like the ZW-WT control. In ZW-Fa(sr) ovotestis, very few germ cells express gamma H2AX & SYCP3 (orange dotted circled areas). In ZZ-E2(sr) ovotestis & ZZ-E2 testis overlain by a cortex, some cortical germ cells express gamma H2AX but none expresses SYCP3. White dotted line highlights the cortical domain borders. See Fig. S4 for the medullary structure of the ZZ-E2, ZW-Fa(sr) & ZZ-E2(sr) models. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32001442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-310202416212348.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - Exposure to DEHP impairs meiotic progression of oocytes from pachytene to diplotene. (a) Immunolabeling of the oocyte chromosomes with anti-SYCP3 antibody (red) & Hoechst 33342 (blue). (b) Effect of DEHP on meiotic progression of oocytes throughout prophase I stages; percentage of each group is presented as mean±SD. Control: 36.27±0.80% pachytene & 54.99±0.66% diplotene; 10 μM & 100 μM DEHP 57.79±4.22% & 56.62±6.62% pachytene & 39.79±4.22% & 36.62±6.62% diplotene, respectively. (c) Representative WB showing the effect of DEHP on the expression of germ cell (DAZL) & meiotic (STRA8 & SCP3) specific proteins. (d) Effect of DEHP on the levels of mRNA in the ovarian tissues of germ cell (Mvh & Dazl), meiotic (Stra8, Rec8, Scp1 & Scp3). All experiments were repeated at least three times independently. (* P<0.05; ** P<0.01) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28771232), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-310202416212391.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - Loss of lamin C2 has no effect on meiotic telomere attachment.(A) 3D-preserved swab preparations showing wildtype (A) & knockout (A′) spermatocytes simultaneously labelled with anti-TRF1 & SUN1 antibodies. As in the wildtype, in lamin C2−/− spermatocytes virtual all telomeres appear to be attached to the NE as indicated by co-localisation of TRF1 & SUN1 signals. Scale bars 5 µm. (B) Quantifications of co-localised & non-co-localised TRF1/SUN1 signals (see A) revealed that ratios of co-localised to non-co-localised spots comparing wildtype & knockout spermatocytes show no significant difference (wildtype n = 33; lamin C2−/− n = 45; Pearson's Chi2 test p-value: 0.799). (C,D) Chromosome spread preparations of pachytene-like lamin C2−/− spermatocytes showing that all telomeres are associated with SUN1. In (C) TeloFISH & in (D) anti-SUN1 staining in co-localisation with SYCP3. Scale bars 10 µm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1003261), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-310202416212363.jpg)
![Immunohistochemistry: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - FANCM expression in human fetal ovaries.(A) Relative FANCM mRNA abundance was measured by RT-qPCR in human fetal ovaries from 5 to 32 weeks post-fertilization (wpf). (B) Germ cells (D2-40+) & somatic cells (D2-40-) were sorted from three ovaries ranging from 8 to 12 wpf & FANCM expression was measured. ACTB was used to normalize FANCM expression in all samples. Dots represent different ovaries & the mean is indicated by the line. (C) Immunohistochemistry of FANCM in human fetal & adult ovaries. Fetal ovaries at 8 & 22 wpf & adult ovaries were studied. FANCM positive cells appear in yellow/brown color (monoclonal FANCM CV5.1 antibody, Novus Biologicals, Abingdon, UK). Ovarian sections were counterstained with hematoxylin (blue staining). Oo, oogonia; Pa, oocyte at the pachytene stage of meiosis I, D, oocyte at the diplotene stage of meiosis I; Pr, oocyte in primordial follicle. (D) Co-staining in 22 wpf ovaries, for FANCM (purple) & DDX4 (brown) confirmed the germ cell identity of FANCM-positive cells (left). Successive staining for FANCM & SYCP3 in the same section (panels a & b). Negative control performed with non-immune mouse IgG (right). Scale bar: 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29231814), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-3102024162184.jpg)
![Immunocytochemistry/ Immunofluorescence: SCP3/SYCP3 Antibody - BSA Free [NB300-232] - Loss of lamin C2 has no effect on meiotic telomere attachment.(A) 3D-preserved swab preparations showing wildtype (A) & knockout (A′) spermatocytes simultaneously labelled with anti-TRF1 & SUN1 antibodies. As in the wildtype, in lamin C2−/− spermatocytes virtual all telomeres appear to be attached to the NE as indicated by co-localisation of TRF1 & SUN1 signals. Scale bars 5 µm. (B) Quantifications of co-localised & non-co-localised TRF1/SUN1 signals (see A) revealed that ratios of co-localised to non-co-localised spots comparing wildtype & knockout spermatocytes show no significant difference (wildtype n = 33; lamin C2−/− n = 45; Pearson's Chi2 test p-value: 0.799). (C,D) Chromosome spread preparations of pachytene-like lamin C2−/− spermatocytes showing that all telomeres are associated with SUN1. In (C) TeloFISH & in (D) anti-SUN1 staining in co-localisation with SYCP3. Scale bars 10 µm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1003261), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-232_rabbit-polyclonal-scp3-sycp3-antibody-310202416212314.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Oxidation causes accumulation of BMAL1. Head and neck cancer cells have different expression levels of the core clock protein BMAL1. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC5173143/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BMAL1-Antibody-Western-Blot-NB100-2288-img0021.jpg "Western Blot: BMAL1 Antibody [NB100-2288] - Oxidation causes accumulation of BMAL1. Head and neck cancer cells have different expression levels of the core clock protein BMAL1. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC5173143/) licensed under a CC-BY license.")
![Immunohistochemistry: BMAL1 Antibody [NB100-2288] - Analysis of BMAL1 in mouse cerebral cortex (left: wt, right: Bmal1 KO) using anti-BMAL1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/BMAL1-Antibody-Chromatin-Immunoprecipitation-NB100-2288-img0018.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BMAL1 Antibody [NB100-2288] - Inhibition of mTOR signaling with Rapamycin rescues PTEN-driven accumulation of BMAL1A. Tissue samples and graphic show BMAL1 in K14cre PtenF/F mice and control (arrows). Note a significant amount of BMAL1 expression in PTEN mutant mice. K14cre PtenF/F mice and control littermates received Rapamycin or vehicle every other day for 15 days. Rapamycin treatment reduces the expression of nuclear BMAL1 in K14cre PtenF/F mice (arrowhead) (*** p0.05). Scale bars -30um. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC5173143/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BMAL1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2288-img0024.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Oxidation causes accumulation of BMAL1. Western blot assay demonstrates time-dependent accumulation of BMAL1 upon oxidative stress in HNSCC cells (*p0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-31020241534364.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Small interference RNA targeting Raptor & Rictor disrupts BMAL1 accumulation in HNSCCTargeted disruption of Raptor (A-B) & Rictor (C-D) using siRNA results in a dose-dependent downregulation of BMAL1 in HNSCC cells. E. Disruption of PTEN by protein oxidation causes activation of mTOR signaling, resulting in accumulation of BMAL1. Notably, inhibition of mTOR signaling, particularly mTORC1 & mTORC2, results in restoration of normal BMAL1 levels in the epidermis of mice & head & neck cancer cells. These results demonstrate a novel role for mTOR in regulating nuclear levels of the core clock gene BMAL1. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-310202415171349.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Targeted disruption of PTEN in vitro & in vivo induces activation of pS6 & BMAL1A. & B. Targeted inhibition of PTEN using siRNA results in concentration-dependent inhibition of PTEN protein in HNSCC cells. HNSCC cells show accumulation of BMAL1 & pS6 in response to PTEN inhibition. C. Immunofluorescence assay to detect BMAL1 in PTEN conditional knockout mice (K14cre PtenF/F) & control littermates. Immunofluorescences & graphic show high accumulation of nuclear BMAL1 in K14cre PtenF/F mice compared to control mice (K14cre). Scale bars represent 50 μm. Black & white images depict cells positive for BMAL1 in K14cre PtenF/F mice (arrows) compared to few BMAL-positive cells in control mice (arrowhead). Scale bars represent 10 μm. (**p<0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-310202415304255.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Small interference RNA targeting Raptor & Rictor disrupts BMAL1 accumulation in HNSCCTargeted disruption of Raptor (A-B) & Rictor (C-D) using siRNA results in a dose-dependent downregulation of BMAL1 in HNSCC cells. E. Disruption of PTEN by protein oxidation causes activation of mTOR signaling, resulting in accumulation of BMAL1. Notably, inhibition of mTOR signaling, particularly mTORC1 & mTORC2, results in restoration of normal BMAL1 levels in the epidermis of mice & head & neck cancer cells. These results demonstrate a novel role for mTOR in regulating nuclear levels of the core clock gene BMAL1. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-31020241538245.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Small interference RNA targeting Raptor & Rictor disrupts BMAL1 accumulation in HNSCCTargeted disruption of Raptor (A-B) & Rictor (C-D) using siRNA results in a dose-dependent downregulation of BMAL1 in HNSCC cells. E. Disruption of PTEN by protein oxidation causes activation of mTOR signaling, resulting in accumulation of BMAL1. Notably, inhibition of mTOR signaling, particularly mTORC1 & mTORC2, results in restoration of normal BMAL1 levels in the epidermis of mice & head & neck cancer cells. These results demonstrate a novel role for mTOR in regulating nuclear levels of the core clock gene BMAL1. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-31020241534379.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Small interference RNA targeting Raptor & Rictor disrupts BMAL1 accumulation in HNSCCTargeted disruption of Raptor (A-B) & Rictor (C-D) using siRNA results in a dose-dependent downregulation of BMAL1 in HNSCC cells. E. Disruption of PTEN by protein oxidation causes activation of mTOR signaling, resulting in accumulation of BMAL1. Notably, inhibition of mTOR signaling, particularly mTORC1 & mTORC2, results in restoration of normal BMAL1 levels in the epidermis of mice & head & neck cancer cells. These results demonstrate a novel role for mTOR in regulating nuclear levels of the core clock gene BMAL1. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-31020241534315.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Targeted disruption of PTEN in vitro & in vivo induces activation of pS6 & BMAL1A. & B. Targeted inhibition of PTEN using siRNA results in concentration-dependent inhibition of PTEN protein in HNSCC cells. HNSCC cells show accumulation of BMAL1 & pS6 in response to PTEN inhibition. C. Immunofluorescence assay to detect BMAL1 in PTEN conditional knockout mice (K14cre PtenF/F) & control littermates. Immunofluorescences & graphic show high accumulation of nuclear BMAL1 in K14cre PtenF/F mice compared to control mice (K14cre). Scale bars represent 50 μm. Black & white images depict cells positive for BMAL1 in K14cre PtenF/F mice (arrows) compared to few BMAL-positive cells in control mice (arrowhead). Scale bars represent 10 μm. (**p<0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-31020241535633.jpg)
![Western Blot: BMAL1 Antibody [NB100-2288] - Oxidation causes accumulation of BMAL1A. Head & neck cancer cells have different expression levels of the core clock protein BMAL1. B. Immunofluorescence assay depicts accumulation of ROS (green channel) & BMAL1 (red channel) upon oxidation. C. & D. Western blot assay demonstrates time-dependent accumulation of BMAL1 upon oxidative stress in HNSCC cells (*p<0.05, **p<0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-310202415363747.jpg)
![Immunocytochemistry/ Immunofluorescence: BMAL1 Antibody [NB100-2288] - Targeted disruption of PTEN in vitro & in vivo induces activation of pS6 & BMAL1A. & B. Targeted inhibition of PTEN using siRNA results in concentration-dependent inhibition of PTEN protein in HNSCC cells. HNSCC cells show accumulation of BMAL1 & pS6 in response to PTEN inhibition. C. Immunofluorescence assay to detect BMAL1 in PTEN conditional knockout mice (K14cre PtenF/F) & control littermates. Immunofluorescences & graphic show high accumulation of nuclear BMAL1 in K14cre PtenF/F mice compared to control mice (K14cre). Scale bars represent 50 μm. Black & white images depict cells positive for BMAL1 in K14cre PtenF/F mice (arrows) compared to few BMAL-positive cells in control mice (arrowhead). Scale bars represent 10 μm. (**p<0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27285754), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-310202415523930.jpg)
![Immunohistochemistry: BMAL1 Antibody [NB100-2288] - Astrocyte Bmal1 regulates genes with conflicting effects on A beta deposition. (A) Topro, GFAP, & BMAL1 staining in CA1 hippocampus of 4-month-old BMAL1 aKO; APP/PS1-21 mice & Cre- controls (scale bar = 100 µm). Arrows indicate astrocyte nuclei quantified as indicated by Topro nuclei surrounded by GFAP positivity. Blue circles indicate nuclei quantified as BMAL1 negative. Quantification of astrocytes counted as BMAL1- or BMAL1+ is shown on the right. n = 5 mice per group, **** = p < 0.0001 by two-way ANOVA with Sidak multiple comparisons test. (B) Heatmap of Fluidigm qPCR analysis of 20 genes involved in the circadian clock, glial activation, & Alzheimer’s Disease in cortex from Aldh1l1-CreERT2; Bmal1fl/fl mice & Cre- controls with or without APP/PS1-21 or APPNL-G-F/wt (n = 6–8 mice per group). Two-way ANOVA analysis: c = significant main effect of Cre genotype, m = main effect of A beta model, c*m = interaction effect of cre & A beta model, - = no significance (all p < 0.05). (C) Individually plotted genes from A. * = p < 0.05, ** = p < 0.005, *** = p < 0.0005 by two-way ANOVA with Sidak multiple comparisons test. Panel B was made using GraphPad Prism version 9.2 (//www.graphpad.com). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35110643), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2288_rabbit-polyclonal-bmal1-antibody-310202415525251.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). A dilution of 1:10 was used. Image objective 40x.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunocytochemistry-Immunofluorescence-NBP2-27103-img0013.jpg "Immunocytochemistry/Immunofluorescence: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). A dilution of 1:10 was used. Image objective 40x.")
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - WB detection of GAPDH protein (theoretical molecular weight: 36 kDa) in HeLa cells lysate using GAPDH antibody (clone 13H12) in (A) the absence and (B) the presence of immunizing peptide.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0001.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of human rectal carcinoma tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0011.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of normal human breast tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0008.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Characterization of lncR492.(B) Northern blot of lncR494 using increasing amounts of loaded total. Black arrow signifies lncR492-specific signal at approximately 1400 bp. A probe targeting Gapdh mRNA served as the loading control. (D) RT-PCR analysis of lncR492 and Gapdh expression. RNA extract was treated with a 5'-phosphate-dependent exonuclease, resulting in a degradation of f.ex. ribosomal RNA.Citation: Winzi M, Casas Vila N, Paszkowski-Rogacz M, Ding L, Noack S, Theis M, et al. (2018) The long noncoding RNA lncR492 inhibits neural differentiation of murine embryonic stem cells. PLoS ONE 13(1): e0191682. //doi.org/10.1371/journal.pone.0191682](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0017.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Serum from trauma patients induces intrinsic apoptosis resistance by up-regulating AAT expression in neutrophils. AAT protein expression was analyzed in neutrophils after 18 h of culture by western blot analysis. Relative expression was quantified vs. GAPDH expression. One representative blot of five independent experiments is depicted. **p<0.01 (one-way ANOVA with Newman keuls post-hoc test). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0177450), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0018.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - WB detection of GAPDH protein (theoretical molecular weight 36 kDa) in lysates of Mouse cell lines (A) NIH 3T3 (B) RAW 264.7 using GAPDH antibody (clone 13H12) at a concentration of 0.25 ug/ml.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0005.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - analysis of GAPDH in HeLa and HEK 293 cells (25ug/lane) using anti-GAPDH antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0014.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of normal human stomach tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0007.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of human colon tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0009.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded tissue section of human esophageal squamous cell carcinoma (SCC) using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0010.jpg)
![Simple Western: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH/G3PDH Antibody (13H12) [NBP2-27103] - Simple Western lane view shows a specific band for GAPDH in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Simple-Western-NBP2-27103-img0015.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-31020241612222.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-310202416114762.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-310202416121949.jpg)
![Western Blot: TRPA1 Antibody [NB110-40763] - Expression and localization of TRPA1 channels in wild-type (WT) and APP/PS1 Tg mice. Brains were harvested from WT and APP/PS1 Tg mice at 8A months old. Western blot analysis of protein levels of TRPA1 and I+--tubulin. Image collected and cropped by Citeab from the following publication (Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease. J Neuroinflammation (2016)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Western-Blot-NB110-40763-img0014.jpg "Western Blot: TRPA1 Antibody [NB110-40763] - Expression and localization of TRPA1 channels in wild-type (WT) and APP/PS1 Tg mice. Brains were harvested from WT and APP/PS1 Tg mice at 8A months old. Western blot analysis of protein levels of TRPA1 and I+--tubulin. Image collected and cropped by Citeab from the following publication (Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease. J Neuroinflammation (2016)) licensed under a CC-BY license.")
![Immunohistochemistry: TRPA1 Antibody [NB110-40763] - Staining TRPA1 in mouse intestine.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Immunohistochemistry-NB110-40763-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TRPA1 Antibody [NB110-40763] - Ai2 elicits TRPA1-dependent Ca2+ influx in astrocytes. Immunostaining of primary astrocytes from WT mice with anti-IgG and anti-TRPA1 antibody, then FITC-conjugated secondary antibody. Image collected and cropped by Citeab from the following publication (Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease. J Neuroinflammation (2016)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-40763-img0011.jpg)
![Flow Cytometry: TRPA1 Antibody [NB110-40763] - An intracellular stain was performed on A549 cells with NB110-40763C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Flow-Cytometry-NB110-40763-img0010.jpg)
![Flow Cytometry: TRPA1 Antibody [NB110-40763] - An intracellular stain was performed on A549 cells with NB110-40763G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488](http://images.novusbio.com/fullsize/TRPA1-Antibody-Flow-Cytometry-NB110-40763-img0009.jpg)
![Western Blot: TRPA1 Antibody [NB110-40763] - The essential role of TRPA1 in Ai2-induced calcium influx in HEK293 cells. (a) Western blot analysis of TRPA1 and I+--tubulin protein levels in non-treated, vector-or TRPA1-transfected HEK293 cells. Image collected and cropped by Citeab from the following publication (Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease. J Neuroinflammation (2016)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Western-Blot-NB110-40763-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: TRPA1 Antibody [NB110-40763] - Analysis of TRPA1 in HEK 293 cells (Flp In Trex system) cells.](http://images.novusbio.com/fullsize/TRPA1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-40763-img0006.jpg)
![Western Blot: TRPA1 Antibody - BSA Free [NB110-40763] - Effects of Lycium barbarum polysaccharides (LBP) & capsaicin (CAP) on colonic (A) Cyclooxygenase-2 (COX-2), (B) Transient receptor potential cation channel V1 (TRPV1), & (C) Transient receptor potential ankyrin 1 (TRPA1) protein expression. (D) Representatives of Western blot for COX-2, TRPV1, TRPA1, & beta -actin. N: control group, U: ulcerative colitis induced group, L: LBP treated group, C: CAP treated group, M: mixed LBP & CAP treated group. Data are presented as mean ± SEM & analyzed by one-way ANOVA & Fisher’s least significant difference test (n = 8). # p < 0.05 compared to the N group. * p < 0.05 compared to the U group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35269566), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40763_rabbit-polyclonal-trpa1-antibody-310202415392558.jpg)
![Immunocytochemistry/ Immunofluorescence: TRPA1 Antibody - BSA Free [NB110-40763] - Expression & localization of TRPA1 channels in wild-type (WT) & APP/PS1 Tg mice. (a) Brains were harvested from WT & APP/PS1 Tg mice at 8 months old. Western blot analysis of protein levels of TRPA1 & alpha -tubulin. Data are mean ± SEM from 6 mice in each group. *, P < 0.05 vs. WT mice. (b, c) Immunohistochemistry of specimens of cortex & hippocampus from 8-month-old WT & APP/PS1 Tg mice with the antibodies anti-TRPA1, anti-vWF (endothelial cell marker), anti-NeuN (neuron marker), anti-GFAP (astrocyte marker) & anti-IBA-1 (microglia marker), then FITC- or Texas red-conjugated secondary antibody. Bar = 50 μm. vWF-positive cells denoted endothelial cells, NeuN-positive cells denoted neurons, & GFAP-positive cells denoted astrocytes, as indicated by arrowheads, stars or arrows, respectively Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0557-z), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40763_rabbit-polyclonal-trpa1-antibody-310202416235534.jpg)
![Immunocytochemistry/ Immunofluorescence: TRPA1 Antibody - BSA Free [NB110-40763] - Evaluation of anti-TRPA1 antibody specificity by western blotting & immunofluorescence. (a) Lysates derived from HEK293T cells transiently transfected with the TRPA1 & GFP expression construct (TRPA1 OE) or TRPM2 & GFP negative control (TRPM2 OE) were probed with the antibodies indicated. Additional untransfected & GFP only controls are presented in the first blot (6G8). Uncropped full length blots are displayed, gaps between the blots are present to indicate the use of a different antibody. Mouse mAbs C-5 & 6G8, & NB110-40763 can detect TRPA1 only in the membrane fraction of lysates at the expected molecular weight (127.5 kDa). Several TRPA1-specific bands are observed above this weight. NB110-40763 also detects several other antigens. Ab58844 & ACC- 037 only appear to detect antigens other than TRPA1 in the conditions used. (b) The performance of the same antibodies was evaluated by immunofluorescence (red) in comparison to the expression of the GFP reporter (green), or control TRPM2 & GFP overexpressing cells as for western blotting. Mouse mAb C-5 again shows high specificity with a strong correlation between the expression of the GFP reporter & antibody staining, & no staining in TRPM2 & GFP overexpressing controls. NB110-40763 also demonstrates some sensitivity but has high background that likely does not correspond to Fc binding of the antibody, as the other two rabbit polyclonal antibodies or isotype control did show different staining patterns. Ab58844 & ACC- 037 only appear to detect antigens other than TRPA1 in the conditions used. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31811235), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40763_rabbit-polyclonal-trpa1-antibody-31020241623556.jpg)
![Western Blot: TRPA1 Antibody - BSA Free [NB110-40763] - Expression & localization of TRPA1 channels in wild-type (WT) & APP/PS1 Tg mice. (a) Brains were harvested from WT & APP/PS1 Tg mice at 8 months old. Western blot analysis of protein levels of TRPA1 & alpha -tubulin. Data are mean ± SEM from 6 mice in each group. *, P < 0.05 vs. WT mice. (b, c) Immunohistochemistry of specimens of cortex & hippocampus from 8-month-old WT & APP/PS1 Tg mice with the antibodies anti-TRPA1, anti-vWF (endothelial cell marker), anti-NeuN (neuron marker), anti-GFAP (astrocyte marker) & anti-IBA-1 (microglia marker), then FITC- or Texas red-conjugated secondary antibody. Bar = 50 μm. vWF-positive cells denoted endothelial cells, NeuN-positive cells denoted neurons, & GFAP-positive cells denoted astrocytes, as indicated by arrowheads, stars or arrows, respectively Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0557-z), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40763_rabbit-polyclonal-trpa1-antibody-310202416235536.jpg)